Publikace na Lékařská fakulta v Plzni, 1. lékařská fakulta |
2023
Abstrakt
Fifty patients (Croatia: 25; Czech Republic: 20; Slovenia: 5) were enrolled. In patients continuing apremilast at 6 (+- 1) months, mean (+- SD) PASI score was reduced from 16.2 +- 8.7 points at treatment initiation to 3.1 +- 5.2 at 6 (+- 1) months; BSA from 11.9% +- 10.3% to 0.8% +- 0.9%; DLQI from 13.7 +- 7.4 points to 1.6 +- 3.2.
PASI 75 was reached by 81% of patients. Physicians reported that the overall treatment success fulfilled their expectations in more than two thirds of patients (68%).
At least three-quarters of patients reported apremilast had a quite or very high benefit on the needs they identified as being most important. Apremilast was well tolerated; no serious or fatal adverse events were identified.